Skip to content

Krystal Biotech, Inc. KRYS Professional Service Fees Payable

Professional Service Fees Payable at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s professional service fees payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s professional service fees payable?
Krystal Biotech, Inc. (KRYS) reported professional service fees payable of $4.35M in Q1 2026.
How has Krystal Biotech, Inc.'s professional service fees payable changed year-over-year?
Krystal Biotech, Inc.'s professional service fees payable increased by 5.6% year-over-year, from $4.12M to $4.35M.
What is the long-term trend for Krystal Biotech, Inc.'s professional service fees payable?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s professional service fees payable has grown at a 56.0% compound annual growth rate (CAGR), from $642K to $5.94M.